한글목차

본 보고서는 제약 및 바이오테크 산업에 대해 조사 분석했으며, 2016-2025년 옵션/평가 거래에 대한 지불 조건 등 상세한 데이터를 제공합니다.

목차

주요 요약

제1장 서론

제2장 옵션/평가 거래 동향

• 서론
• 옵션/평가 거래 정의
• 옵션/평가 거래 동향(2019년 이후)
  • 옵션/평가 거래 : 연도별(2019년-2025년)
  • 옵션/평가 거래 : 개발 단계별(2019년-2025년)
  • 옵션/평가 거래 : 산업 부문별(2019년-2025년)
  • 옵션/평가 거래 : 치료 영역별(2019년-2025년)
  • 옵션/평가 거래 : 기술 유형별(2019년-2025년)
  • 옵션/평가 거래 : 가장 활발한 기업별(2019년-2025년)
• 옵션/평가 파트너 거래를 체결하는 이유
• 옵션/평가 거래 향후

제3장 옵션/평가 거래 구조 개요

• 서론
• 옵션/평가 거래 구조

제4장 주요 옵션/평가 거래

• 서론
• 주요 옵션/평가 거래(금액)

제5장 가장 활발한 옵션/평가 거래 기업 상위 25개사

• 서론
• 가장 활발한 옵션/평가 거래 기업 상위 25개사

제6장 옵션/평가 거래와 계약 디렉토리

• 서론
• 옵션/평가 거래와 계약(2019년-2025년)
• 계약 디렉토리
• 계약 디렉토리 - 옵션/평가 거래 : 기업별(A-Z)
• 계약 디렉토리 - 옵션/평가 거래 : 치료 영역별
• 계약 디렉토리 - 옵션/평가 거래 : 기술 유형별
• Biopharma Research에 대해
• Current Partnering
• Current Agreements
• Current Partnering의 최근 보고서 제목

영문목차

Option and Evaluation Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter option and evaluation deals.

Fully revised and updated, the report provides details of option and evaluation deals from 2019 to 2025.

The report provides access to option and evaluation deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of option and evaluation deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual option and evaluation contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of option and evaluation dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in option and evaluation as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of option and evaluation deals.

Chapter 4 provides a review of the leading option and evaluation deals since 2019. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 25 most active option and evaluation dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 6 provides a comprehensive and detailed review of option and evaluation deals organized by company A-Z, therapy, technology and industry type signed and announced since 2019 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the option and evaluation deal.

The deal directory includes a comprehensive listing of all option and evaluation deals announced since 2019. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in option and evaluation dealmaking since 2019.

In conclusion, this report provides everything a prospective dealmaker needs to know about option and evaluation alliances.

Key benefits

Option and Evaluation Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:

• Understand deal trends since 2019
• Browse option and evaluation deals
• Benchmark analysis - identify market value of transactions
• Financials terms
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Option and Evaluation Deals in Pharmaceuticals and Biotechnology is intended to provide the reader with an in-depth understanding of the option and evaluation trends and structure of deals entered into by leading biopharma companies worldwide.

Option and Evaluation Deals in Pharmaceuticals and Biotechnology includes:

• Trends in option and evaluation dealmaking in the biopharma industry
• Overview of option and evaluation deal structure
• Directory of option and evaluation deal records covering pharmaceutical and biotechnology
• The leading option and evaluation deals by value
• Most active option and evaluation dealmakers
• The leading option and evaluation partnering resources

In Option and Evaluation Deals in Pharmaceuticals and Biotechnology, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Option and Evaluation Deals in Pharmaceuticals and Biotechnology provides comprehensive access to available records for option and evaluation deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the rights granted or optioned?
• What rights are granted by the agreement?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are intellectual property rights handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in option and evaluation dealmaking

• 2.1. Introduction
• 2.2. Definition of option and evaluation deal
• 2.3. Trends in option and evaluation deals since 2019
  • 2.3.1. Option and evaluation dealmaking by year, 2019-2025
  • 2.3.2. Option and evaluation dealmaking by phase of development, 2019-2025
  • 2.3.3. Option and evaluation dealmaking by industry sector, 2019-2025
  • 2.3.4. Option and evaluation dealmaking by therapy area, 2019-2025
  • 2.3.5. Option and evaluation dealmaking by technology type, 2019-2025
  • 2.3.6. Option and evaluation dealmaking by most active company, 2019-2025
• 2.4. Reasons for entering into option and evaluation partnering deals
• 2.5. The future of option and evaluation deals

Chapter 3 - Overview of option and evaluation deal structure

• 3.1. Introduction
• 3.2. Option and evaluation agreement structure

Chapter 4 - Leading option and evaluation deals

• 4.1. Introduction
• 4.2. Top option and evaluation deals by value

Chapter 5 - Top 25 most active option and evaluation dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active option and evaluation dealmakers

Chapter 6 - option and evaluation deals including contracts directory

• 6.1. Introduction
• 6.2. Option and evaluation deals with contracts 2019-2025
• Deal directory
• Deal directory - option and evaluation dealmaking by companies A-Z
• Deal directory - option and evaluation dealmaking by therapy area
• Deal directory - option and evaluation dealmaking by technology type
• About Biopharma Research
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of option and evaluation
• Figure 2: Trends in option and evaluation deal announcements, 2019-2025
• Figure 3: Option and evaluation deals signed at each phase of development, 2019-2025
• Figure 4: Option and evaluation deals by industry sector, 2019-2025
• Figure 5: Option and evaluation deals by therapy area, 2019-2025
• Figure 6: Option and evaluation deals by technology type, 2019-2025
• Figure 7: Top 25 most active option and evaluation dealmakers, 2019-2025
• Figure 8: Top option and evaluation deals by value, 2019-2025
• Figure 9: Most active option and evaluation dealmakers, 2019-2025